Evidence map›Paper›PMID 40507334›Full record

ArticleCancers2025

Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.

Andrew J Kinloch, Faiyaz Rahman, Bahriye Karakas, Muhammad Shahid, Bora Lim, Stephanie J Bouley, James A Walker, Erinna F Lee, Walter D Fairlie, Kevin R Kelly and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrew J KinlochEutropics Pharmaceuticals, Cambridge, MA 02138, USA.ORCID 0009-0008-0724-4610
Faiyaz RahmanEutropics Pharmaceuticals, Cambridge, MA 02138, USA.ORCID 0000-0002-7993-3318
Bahriye KarakasEutropics Pharmaceuticals, Cambridge, MA 02138, USA.
Muhammad ShahidEutropics Pharmaceuticals, Cambridge, MA 02138, USA.
Bora LimMD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4182-6058
Stephanie J BouleyCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0003-0785-0860
James A WalkerCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-5585-698X
Erinna F LeeOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0003-1255-9808
Walter D FairlieOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0002-2498-1160
Kevin R KellyKeck School of Medicine of USC, Los Angeles, CA 90033, USA.
Michael H CardoneEutropics Pharmaceuticals, Cambridge, MA 02138, USA.ORCID 0000-0001-6484-5473

Funding

Commercializing Praedicare Dx TM platform for guiding cancer treatmentsR44CA203610 · NCI · EUTROPICS PHARMACEUTICALS, INC. · PI CARDONE, MICHAEL H · 2017 to 2019
$3.0M
NCI NIH HHS R44 CA203610NIH HHS Grant # 2R44CA203610-02A1
6 · The paper itself

Abstract

One of the hallmarks of cancer cells is their failure to respond to the cellular mechanism of apoptosis. The B-cell lymphoma 2 (BCL-2) family of proteins regulate apoptosis. Their ability to do so can be measured using several methods that in turn anticipate the fate of the cancer cell in response to apoptosis-inducing treatment. These assays ultimately identify the readiness of the cancer cell to undergo apoptosis, which is referred to as the mitochondrial priming state. These metrics, however, have been challenging to implement in the clinic.

Indexed as

AMLapoptosisBH3 domainBH3 mimeticsflow cytometrymitochondrial primingPRIMAB

Identifiers

PMID40507334
PMCPMC12153628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.